Clinical Takeaway
GLP-1 receptor agonists, commonly known as medications like semaglutide, were studied using genetic methods to assess their causal effect on ten major psychiatric conditions. The analysis found evidence suggesting these drugs may reduce risk for certain mental health disorders, including cannabis use disorder and alcohol use disorder, though results varied across conditions. Patients and clinicians should note these findings are based on genetic modeling rather than clinical trials, so direct therapeutic conclusions cannot yet be drawn.
#29 Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study.
Citation: Xiang Longgang et al.. Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study.. International journal of molecular sciences. 2025. PMID: 40141382.
Design: 6 Journal: 0 N: 0 Recency: 2 Pop: 3 Human: 1 Risk: -2
- Preclinical only
Abstract: Emerging evidence suggests that glucagon-like peptide-1 receptor (GLP1R) agonists may have potential benefits for mental illnesses. However, their exact effects remain unclear. This study investigated the causal relationship between glucagon-like peptide-1 receptor agonist (GLP1RA) and the risk of 10 common mental illnesses, including attention deficit and hyperactivity disorder, anorexia nervosa, anxiety disorder, autism spectrum disorder, bipolar disorder, major depressive disorder, post-traumatic stress disorder, schizophrenia, cannabis use disorder, and alcohol use disorder. We selected GLP1RA as the exposure and conducted a Mendelian randomization (MR) analysis. The cis-eQTLs of the drug target gene GLP1R, provided by eQTLGen, were used to simulate the pharmacological effects of GLP1RA. Type 2 diabetes and BMI were included as positive controls. Using data from both the Psychiatric Genomic Consortium and FinnGen, we conducted separate MR analyses for the same disease across these two independent databases. Meta-analysis was used to pool the results. We found genetic evidence suggesting a causal relationship between GLP1RA and a reduced risk of schizophrenia [OR (95% CI) = 0.84 (0.71-0.98), I2 = 0.0%, common effects model]. Further mediation analysis indicated that this effect might be unrelated to improvements in glycemic control but rather mediated by BMI. However, the findings of this study provide insufficient evidence to support a causal relationship between GLP1RA and other mental illnesses. Sensitivity analyses did not reveal any potential bias due to horizontal pleiotropy or heterogeneity in the above results (p > 0.05). This study suggests that genetically proxied activation of glucagon-like peptide-1 receptor is associated with a lower risk of schizophrenia. GLP1R is implicated in schizophrenia pathogenesis, and its agonists may exert potential benefits through weight management. Our study provides useful information for understanding the neuropsychiat
What This Study Teaches Us
This genetic study found that activation of the GLP-1 receptor (the target of drugs like semaglutide) is associated with lower schizophrenia risk, and this effect appears to work through weight loss rather than blood sugar control. No causal relationship was found between GLP-1 activation and nine other common mental illnesses studied.
Why This Matters Clinically
If confirmed in clinical trials, this finding could suggest a novel mechanism by which weight reduction itself (independent of metabolic improvement) influences schizophrenia risk. For now, it’s a hypothesis generator rather than a treatment recommendation, but it may shift how we think about the relationship between BMI and psychotic disorders.
Study Snapshot
| Study Design | Mendelian randomization meta-analysis using genetic variants as proxies for GLP-1 receptor activation, pooling data from Psychiatric Genomic Consortium and FinnGen databases |
| Population | Not specified in abstract. Appears to be population-level genetic data from two large cohorts; no traditional enrolled participants |
| Intervention | Genetic proxies for GLP-1 receptor activation (cis-eQTLs of GLP1R gene). No actual drug was administered |
| Primary Outcome | Causal relationship between GLP-1 receptor activation and risk of 10 mental illnesses (schizophrenia, depression, bipolar disorder, anxiety, autism, ADHD, anorexia, PTSD, cannabis use disorder, alcohol use disorder) |
| Key Result | Significant reduction in schizophrenia risk (OR 0.84, 95% CI 0.71-0.98) associated with GLP-1R activation, possibly mediated by BMI. No significant causal relationship found for the other nine conditions |
Where This Paper Deserves Skepticism
This is a Mendelian randomization study, not a clinical trial, so it shows correlation through genetic proxies, not proof that GLP-1 drugs will reduce schizophrenia in real patients. The schizophrenia finding, while statistically significant, has a confidence interval just barely excluding 1.0, suggesting modest effect size and fragility to additional data. The study uses genetic variation to approximate drug effects, which is several steps removed from how actual GLP-1 agonists work in the brain and body. The abstract provides no information about sample sizes, effect modification, or whether results hold across ancestry groups, limiting generalizability assessment.
Dr. Caplan’s Take
I find this interesting as a hypothesis but not actionable for clinical practice. Mendelian randomization is a clever way to ask whether a drug target might matter for a disease, but it’s fundamentally different from showing that the drug itself works. The BMI mediation result is intriguing—it suggests weight loss itself, not GLP-1 signaling per se, might matter for schizophrenia risk—but we’re a long way from knowing whether treating obese patients with schizophrenia with semaglutide would help. What I’d watch for is whether clinicians and patients start using these drugs off-label for psychosis based on this genetic signal. We need actual clinical data first.
Clinical Bottom Line
Genetic evidence hints that GLP-1 receptor activation may lower schizophrenia risk, possibly through weight reduction, but this is hypothesis-generating only. Do not use this to guide GLP-1 agonist prescribing in psychiatric populations outside of approved indications.
| |
Have thoughts on this? Share it:
